Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222286 · ClinicalTrials.gov registry record · Phase 2
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
A Phase 2 study of Smoldering Multiple Myeloma, sponsored by Innate Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT01222286: Completed Phase 2 study of Smoldering Multiple Myeloma, sponsored by Innate Pharma.
NCT01222286 is a Phase 2 study of Smoldering Multiple Myeloma that has completed, run by Innate Pharma. The registered enrollment target is 30 participants, below the 798-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01222286, a Phase 2 study of Smoldering Multiple Myeloma, has completed, sponsored by Innate Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
Primary Outcome
The primary end point is the rate of patients achieving an objective response (defined according to the International Myeloma Working Group uniform response criteria), including minimal response, (as derived from the European Society for Blood and Marrow Transplantation criteria), achieved at any time until end of study and confirmed on two consecutive assessments at 4 weeks interval.
Conditions Studied
Interventions
- DRUG IPH2101
Study Locations (5)
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Mount Sinai School of Medicine - New York
Ohio
- Ohio State University - Columbus
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT01222286 record still lists
NCT01222286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 798-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which IPH2101 is the first listed.
NCT01222286 lists 5 locations in 5 states (Massachusetts, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT01222286 about?
NCT01222286 is a clinical study titled "Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma". The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
What is the current status of trial NCT01222286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2010-09. Estimated completion is 2013-01.
What conditions does trial NCT01222286 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
What interventions are being tested in trial NCT01222286?
The interventions under investigation include: IPH2101 (DRUG).
Who is sponsoring clinical trial NCT01222286?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01222286 being conducted?
This trial has 5 study locations across Massachusetts, New York, Ohio, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01222286's enrollment target sits among peer trials
30 17th of 20 higher than 4 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
ACTIVE NOT RECRUITING · Phase 2
-
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia